Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Share:
Related GSK
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys
Clinical Trial Patients' Positive Experiences Bode Well For Genocea's Billion Dollar HSV Drug (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...